Investment case
ENDRA Life Sciences Inc.
NDRA · 3 developments mapped · last assessed 2026-08-21
Market Ontology has mapped 3 macro, policy, and market developments to ENDRA Life Sciences Inc. since 2026-08-17. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.
Valuation
No validated run has been published for NDRA yet, so no modelled value is shown. The NDRA valuation is in the public catch-up queue.
Subscribers do not wait for the weekly cycle: they run NDRA on demand, against live prices and the latest filings, and change any assumption the developments below move.
Filed financials
Current case
- Strongest support
ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc.
Direct impact from acquisition premium and increased certainty of value realization for shareholders.
· Moves implied acquisition price per share, probability of deal completion
- Open question
ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc.
Direct impact from acquiring a new business (Renergen) and a complete strategic pivot. This will fundamentally change NDRA's business model, revenue streams, and risk profile.
· Moves future growth rate of the combined helium business, cost of capital for the new business model, synergy realization from the merger
What changed, by assumption
- 2026-08-21ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc.
- 2026-08-21ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc.
- 2026-08-17ENDRA Life Sciences Inc. to Acquire Noble Africa LLC
Assumption changes
Full ledger →| Date | Assumption | Direction | Why | Conf. |
|---|---|---|---|---|
| 2026-07-22 | Valuation multiple | Bearish | Incremental float typically compresses near-term multiple absent revenue acceleration. | 0.70 |
| 2026-07-22 | Share count | Bullish | Primary equity issuance increases diluted share count. | 0.70 |
| 2026-06-25 | Valuation multiple | Bullish | Target re-rates to bid premium until close. | 0.70 |
| 2026-06-25 | Share count | Bullish | Stock component of consideration dilutes existing acquirer holders. | 0.70 |
| 2026-06-25 | Net debt | Bullish | Cash component of consideration is typically debt-funded, raising net debt. | 0.70 |
| 2026-06-25 | Revenue | Bullish | Acquisition adds target revenue to acquirer P&L on close. | 0.70 |
Event impact log
Full ledger →| Date | Mechanism | Direction | Horizon | Impact |
|---|---|---|---|---|
| 2026-08-21 | ASP Isotopes Inc. to Merge Renergen Asset into ENDRA Life Sciences Inc. | mixed | 3-12m | 0.80 |
| 2026-08-21 | ASP Isotopes Inc. to Acquire ENDRA Life Sciences Inc. | Bullish | intraday | 0.80 |
| 2026-08-17 | ENDRA Life Sciences Inc. to Acquire Noble Africa LLC | mixed | 1-3m | 0.80 |